BioSpace News Archive

Extremely high patient satisfaction and clinician confidence drive adoption

Entest Group, Inc. (OTC: ETNI) declared the distribution on a pro rata basis as a dividend in kind of 3,000,000...

First-ever CT system cleared by the FDA for enhanced intraoperative margin assessment of biopsies and lumpectomies.

FIX-HF-5C Late-Breaking Clinical Trial Data Presented at HRS 2018 with Simultaneous Publication in the Journal of the American College of Cardiology: Heart Failure

Neovasc Inc. announced today that it has regained compliance with the minimum market value from The Nasdaq Stock Market LLC

TRULANCE only CIC/IBS-C Rx brand to grow in total and new Rx volume quarter-over-quarter, per IQVIA Synergy lowers 2018 adjusted operating expense (non-GAAP) guidance

ESSA Pharma Inc. (“ESSA” or the “Company”) (TSX-V: EPI, Nasdaq: EPIX), a pre-clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced today that it received a notice from the Nasdaq Listing Qualifications Staff on May 10, 2018 notifying the Company that it regained compliance with the Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “Nasdaq”

SQI Diagnostics and Microdrop Launch Revolutionary Disease Awareness Tests for Direct-to-Consumer Market

Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX: NRI; OTCQX: NRIFF) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2018 Annual and Special Meeting of Shareholders held on May 10, 2018 in Mississauga, all nominees listed in the management proxy circular dated March 29, 2018 were elected as directors of the Company.

TSO3 Inc. (TSX: TOS), (“TSO3" or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the nominees listed in the management proxy circular dated April 3, 2018, were elected as directors of TSO3. In addition, all other proposals submitted by management were approved.